Researchers at UW Medicine and the Fred Hutchinson Cancer Research Center are jointly testing monoclonal antibodies created by Regeneron Pharmaceuticals to prevent COVID-19, and are starting to recruit patients. The scientists are testing a double antibody cocktail called REGN-COV2 (REGN10933+REGN10987), which had favourable results in mouse models and a positive review of the Phase I safety evaluation in...
